Results 201 to 210 of about 918,244 (327)

SYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Recurrent high‐grade gliomas have a poor prognosis and limited therapeutic options. This study aimed to evaluate the safety and efficacy of SYHA1813, a dual inhibitor of VEGFR and CSF1R, in patients with recurrent high‐grade gliomas.
Zhuang Kang   +16 more
wiley   +1 more source

A two-site immunoenzymometric assay of 52-kDa pro-cathepsin D, and its use in human breast diseases. [PDF]

open access: bronze, 1989
Gilles Freiss   +4 more
openalex   +1 more source

Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).
Nizar Chahin   +10 more
wiley   +1 more source

Benign Breast Diseases. [PDF]

open access: yesBreast Care (Basel), 2018
Thill M.
europepmc   +1 more source

Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients [PDF]

open access: bronze, 1985
Arto Alanko   +4 more
openalex   +1 more source

Pagetʼs Disease of the Breast

open access: green, 1970
Francis C. Nance   +3 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy